Veru Inc. (VERU): Price and Financial Metrics
VERU Stock Summary
- With a price/earnings ratio of 419.22, Veru Inc P/E ratio is greater than that of about 97.86% of stocks in our set with positive earnings.
- The price/operating cash flow metric for Veru Inc is higher than 99.02% of stocks in our set with a positive cash flow.
- The volatility of Veru Inc's share price is greater than that of 96.97% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Veru Inc, a group of peers worth examining would be SURF, SGEN, EXEL, SLAB, and NVMI.
- VERU's SEC filings can be seen here. And to visit Veru Inc's official web site, go to www.verupharma.com.
VERU Stock Price Chart Interactive Chart >
VERU Price/Volume Stats
|Current price||$8.82||52-week high||$24.57|
|Prev. close||$9.09||52-week low||$2.30|
|Day high||$9.14||Avg. volume||3,707,259|
|50-day MA||$13.41||Dividend yield||N/A|
|200-day MA||$6.71||Market Cap||634.26M|
Veru Inc. (VERU) Company Bio
Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is based in Miami, Florida.
VERU Price Forecast Based on DCF Valuation
|Current Price||DCF Fair Value Target:||Forecasted Gain:|
Below please find a table outlining a discounted cash flow forecast for VERU, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Veru Inc ranked in the 5th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 98%. In terms of the factors that were most noteworthy in this DCF analysis for VERU, they are:
- The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than only 7.02% of the free cash flow producing stocks we're observing.
- As a business, Veru Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.
|Terminal Growth Rate in Free Cash Flow||Return Relative to Current Share Price|
VERU Latest News Stream
|Loading, please wait...|
VERU Latest Social Stream
View Full VERU Social Stream
Latest VERU News From Around the Web
Below are the latest news stories about Veru Inc that investors may wish to consider to help them evaluate VERU as an investment opportunity.
The S&P 500 rose to another record high on Friday, and at least one strategist believes we’re at the start of a new bull market. Writing from LPL Financial, chief market strategist Ryan Detrick noted several market-historical points that indicate sustained gains are in the offing. Key among his points are the first quarter returns and the breadth of the current stock rally. On returns, Detrick highlights that the S&P 500 gained nearly 6% in Q1 – and that the 6% level has been an accurate indicator for near-term trends.
Veru (NASDAQ:VERU) showed a loss in earnings since Q4, totaling $777.00 thousand. Sales, on the other hand, increased by 24.41% to $14.62 million during Q1. Veru collected $11.75 million in revenue during Q4, but reported earnings showed a $11.27 million loss. Why ROCE Is Significant Changes in earnings and sales indicate shifts in Veru's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Veru posted an ROCE of 0.02%. It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affec...
Atossa Therapeutics (NASDAQ:ATOS) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, analyst recommendations, institutional ownership and dividends. Volatility & Risk Atossa Therapeutics has a beta of 2.34, suggesting that its share price is […]
Veru Inc (NASDAQ: VERU) has engaged Morgan Stanley as a financial advisor to pursue strategic alternatives for its legacy Female Healthcare Business. "Furthermore, with the potential for five registration clinical trials in the calendar year 2021, four for oncology indications and one for COVID-19 it is clear that Veru has transformed itself into a premium, late-stage, clinical biopharmaceutical company, so the strategic fit with the FHC Business is not as strong as it once was," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer. For the fiscal year 2020, the business reported net revenues of $41 million and gross profit of $29 million. Its commercial product is the FC2 Female Condom/ FC2 Internal Condom, the only FDA-approved female condom. Price Action: VER...
Shares of Veru Inc. gained 6.5% in trading on Monday after the company said it is considering selling its female condom product. Veru hired Morgan Stanley & Co. as its financial advisor, saying the female condom business was no longer a strategic fit for the company now that it is advancing oncology and COVID-19 products through clinical trials. "It is clear that Veru has transformed itself into a premium, late-stage, clinical biopharmaceutical company, so the strategic fit with the [female health company] business is not as strong as it once was," Dr. Mitchell Steiner, Veru's president and CEO, said in a news release. The female condom business generated $41 million in net revenue in 2020, though the sexual health product, which is the only one of its kind, makes up less than 2% of tot...
VERU Price Returns
Continue Researching VERUWant to do more research on Veru Inc's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!